ThomasFImperialeMD
Gastroenterology • Indianapolis, INProfessor, Medicine, Indiana University School of Medicine
Dr. Imperiale is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
550 University Blvd
# UH4100
Indianapolis, IN 46202Phone+1 317-944-8660Fax+1 812-933-3729
Education & Training
The MetroHealth System/Case Western Reserve UniversityFellowship, Gastroenterology, 1992 - 1994
Yale-New Haven Medical CenterResidency, Internal Medicine, 1985 - 1987
Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Internal Medicine, 1981 - 1984
New York University School of MedicineClass of 1981
Certifications & Licensure
IN State Medical License 1996 - 2025
OH State Medical License 1984 - 2000
PA State Medical License 2000 - 2000- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Gastroenterology
Awards, Honors, & Recognition
- Fellow (AGAF) American Gastroenterological Association, 2009
- Fellow (FACP) American College of Physicians, 1995
Clinical Trials
- Colonoscopy Versus Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM) Start of enrollment: 2012 Apr 30
- A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval Start of enrollment: 2015 Apr 01
- Clinical Validation of An Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, for Colorectal Cancer Screening "BLUE-C" Start of enrollment: 2019 Nov 15
- Join now to see all
Publications & Presentations
PubMed
- 353 citationsMultitarget stool DNA testing for colorectal-cancer screening.Thomas F Imperiale, David F Ransohoff, Steven H Itzkowitz, Theodore R Levin, Philip Lavin
The New England Journal of Medicine. 2014-04-03 - 25 citationsSpecificity of the Multi-Target Stool DNA Test for Colorectal Cancer Screening in Average-Risk 45-49 Year-Olds: A Cross-Sectional Study.Thomas F. Imperiale, John B. Kisiel, Steven H. Itzkowitz, Bradley Scheu, Emma Kate Duimstra
Cancer Prevention Research. 2021-01-12 - 29 citationsCost Effectiveness of Different Strategies for Detecting Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Based on United States Health Care SystemEduardo Vilar-Gomez, Zhouyang Lou, Nan Kong, Raj Vuppalanchi, Thomas F. Imperiale
Clinical Gastroenterology and Hepatology. 2020-09-01
Journal Articles
- Thinking Big About Small Adenomas: Moving Towards “Precision Surveillance”Thomas Imperiale, MD, Nature
Press Mentions
FDA Approves Exact Sciences’ Non-Invasive Test for Colorectal Cancer ScreeningOctober 4th, 2024- FDA Approves Exact Sciences’ Cologuard plus Test, Setting a New Benchmark in Non-Invasive Colorectal Cancer ScreeningOctober 4th, 2024
- Geneoscopy to Present at Gastroenterology and Cancer Surveillance Conferences, Highlighting Advancements in Colorectal Cancer Screening and Early DetectionAugust 14th, 2024
- Join now to see all
Grant Support
- Neoplastic Yield Of Colonoscopy In The VA Health Care SystemVeterans Affairs2011
- Neoplastic Yield Of Colonoscopy In The VA Health Care SystemHealth Services Research &Development2009
- Quantifying Risk To Target Screening ColonoscopyNational Cancer Institute2004–2009
- Using Risk To Tailor Management Of Digestive DiseasesNational Institute Of Diabetes And Digestive And Kidney Diseases2004–2008
- Risk Stratification For Prevalent Digestive DiseasesNational Institute Of Diabetes And Digestive And Kidney Diseases1999–2003
Professional Memberships
- Fellow
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
